BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation

Am J Hematol. 2024 Jun;99(6):1180-1183. doi: 10.1002/ajh.27291. Epub 2024 Mar 25.

Robert Stuver¹, Agrima Mian², Samantha Brown³, Sean Devlin³, Paolo F Caimi², Stephanie Chinapen⁴, Parastoo Dahi^{4

5}, Robert Dean², Zachary D Epstein-Peterson¹, Brian Hill², Steven M Horwitz^{1

5}, Oscar Lahoud^{1

4

5}, Richard Lin^{4

5}, Alison J Moskowitz¹, Craig Sauter², Gunjan Shah^{4

5}, Alison Winter², Deepa Jagadeesh², Michael Scordo^{4

5}

¹ Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
³ Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁴ Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁵ Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Abstract